-
P191 Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16: results from COAST-V trial
Sofía Ramiro, Cédric Lukas, Michael John Nissen, Yves Schymura, Khai Jing Ng, Gabriel Doridot, +3 more
0citations -
E068 Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Xenofon Baraliakos, Sofía Ramiro, Marina Magrey, Martín Rudwaleit, Nigil Haroon, Carmen Fleurinck, +5 more
0citations -
Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study
Omar-Javier Calixto, Xenofon Baraliakos, Annelies E. R. C. H. Boonen, Wilson Bautista‐Molano, Ivette Essers, Désirée M F M van der Heijde, +2 more
0citations